Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Acute kidney injury (AKI) is still associated with high morbidity and mortality incidence rates, and also bears an elevated risk of chronic kidney disease in the sequel. Whereas the kidney has a remarkable capacity for regeneration after injury and may recover completely depending on the type of renal lesions, the options for clinical intervention are restricted to fluid management and extracorporeal kidney support. The development of novel therapies to prevent AKI, to improve renal regeneration capacity after AKI, and to preserve renal function—in both the short- and long-term—is urgently needed. This Special Issue includes papers investigating the pathological mechanisms of renal inflammation and AKI and diagnostics using new biomarkers. Furthermore, experimental in vitro and in vivo studies examining potential new approaches to attenuate kidney dysfunction are included, as well as review articles.

inflammation --- chronic kidney disease --- anemia --- anemia of inflammation --- ESA hyporesponsiveness --- renal tubular epithelial cells --- macrophages --- lipocalin-2 --- iron --- cilastatin --- hypoxia inducible factor-1-α --- ischemia-reperfusion injury --- acute kidney injury --- cyclophilin A --- fibrosis --- renal fibrosis --- tubular necrosis --- preeclampsia --- podocytes --- VEGF --- FSGS --- proteinuria --- endocan --- ESM-1 --- renal replacement therapy --- kidney transplantation --- biomarker --- diabetic nephropathy --- focal segmental glomerulosclerosis --- innate immunity --- membranous nephropathy --- minimal change diseases --- TLR --- NOX1 --- ML171 --- reactive oxygen species --- ERK --- T cells --- glomerulonephritis --- chemokines --- renal disease --- DJ-1 --- ND-13 --- renal inflammation --- oxidative stress --- UUO --- autophagy --- apoptosis --- trehalose --- simvastatin --- endotoxin --- tubular apoptosis --- cytochrome C --- Bcl-XL --- survivin --- hypercholesterolemia --- xanthine oxidase --- NF-κB pathway --- tertiary lymphoid organs --- B cells --- BAFF --- kidney fibrosis --- myofibroblast activation --- extracellular matrix --- Hippo pathway --- verteporfin --- IgAN --- CKD --- progression --- ACEI --- corticosteroids --- costimulation --- coinhibition --- kidney transplant --- SPR --- protein binding affinity --- adaptive immunity --- epithelial-to-mesenchymal transition --- E. cava extracts --- dieckol --- spontaneously hypertensive rats --- angiotensin II --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Poly(lactic-co-glycolic acid) (PLGA) is one of the most successful polymers used for producing therapeutic devices, such as drug carriers (DC). PLGA is one of the few polymers that the Food and Drug Administration (FDA) has approved for human administration due to its biocompatibility and biodegradability. In recent years, DC produced with PLGA has gained enormous attention for its versatility in transporting different type of drugs, e.g., hydrophilic or hydrophobic small molecules, or macromolecules with a controlled drug release without modifying the physiochemical properties of the drugs. These drug delivery systems have the possibility/potential to modify their surface properties with functional groups, peptides, or other coatings to improve the interactions with biological materials. Furthermore, they present the possibility to be conjugated with specific target molecules to reach specific tissues or cells. They are also used for different therapeutic applications, such as in vaccinations, cancer treatment, neurological disorder treatment, and as anti-inflammatory agents. This book aims to focus on the recent progress of PLGA as a drug carrier and their new pharmaceutical applications.

PLGA --- nanoscaled drug delivery --- LED --- cancer --- serum stability --- reactive oxygen species --- cellular uptake --- terahertz spectroscopy --- microspheres --- drug delivery --- formulation development --- molecular mobility --- vitamin E --- tocopherol --- PLA --- core-shell nanoparticles --- controlled drug release --- BMP-2 --- PLGA nanoparticles --- Pluronic F68 --- oxaliplatin --- hydrogel --- intra-abdominal anti-adhesion barrier --- colorectal cancer --- experimental design --- fractional factorial design --- O6-methylguanine DNA methyltransferase (MGMT) protein --- glioblastoma multiforme --- smart nanocarriers --- folic acid --- verteporfin --- cisplatin --- SKOV-3 cells --- CHO-K1 cells --- electroporation --- theranostic cargo --- double emulsion approach --- NSAIDs --- polymeric film --- topical drug delivery --- trolamine salicylate --- triamcinolone acetonide --- microcrystal --- PLGA microsphere --- local delivery --- spray-drying technique --- intra-articular injection --- joint retention --- systemic exposure --- gadolinium --- drug release --- polymeric nanocarrier --- sorafenib --- theranostic nanoparticles --- PLGA-PEG --- nanoparticles --- platelet --- activation --- aggregation --- binding --- uptake --- tissue engineering --- Huntington’s disease --- siRNA --- microcarriers --- mesenchymal stromal cells --- drug delivery systems --- microfluidics --- microparticles --- BMP-2-microspheres --- hydrogel system --- 17-βestradiol release --- bone regeneration --- osteoporosis --- poly-lactide-co-glycolide --- polylactic acid --- alginate --- ophthalmic drug delivery --- dexamethasone --- PLGA-NPs --- nanomedicine --- gastrointestinal tract --- paclitaxel --- in vivo imaging --- controlled release --- risperidone --- microcapsules --- oleogels --- electron microscopy --- three-dimensional X-ray imaging --- nano-CT --- biodegradable polymers --- hydroxy-stearic acid --- PLGA nanocapsules --- magnetic resonance imaging --- photoluminescence --- magnetic targeting --- multimodal imaging --- theranostics --- silicon --- microsphere --- n/a --- Huntington's disease

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This special issue brings together cutting edge research and insightful commentary on the currentl state of the Cancer Nanomedicine field.

Technology: general issues --- antibody drug conjugate (ADC) --- PD-L1 --- tumor spheroid disruption --- immune modulation --- doxorubicin --- graphene oxide --- adsorption --- cathepsin D --- cathepsin L --- anti-metastatic enzyme cancer therapy --- nanoparticles --- targeted delivery system --- siRNA --- osteopontin --- mammary carcinoma --- mesenchymal stem cells (MSCs) --- TAT peptide --- PLGA --- paclitaxel --- nano-engineered MSCs --- orthotopic lung tumor model --- intracranial glioma --- immunotherapy --- CPMV --- viral nanoparticles --- in situ vaccine --- albumin nanoparticles --- microbubble --- ultrasound --- theranostics --- hepatocellular carcinoma --- VX2 tumor --- intra-arterial chemotherapy --- lung cancer --- nanomedicine --- clinical status --- cancer therapy --- breast cancer --- cell signaling --- active targeting --- passive targeting --- EPR effect --- oncogenes --- nanoparticle --- drug delivery --- ligand --- tumor targeting --- biodistribution --- Mesoporous silica nanoparticle --- drug delivery system --- target treatment --- lanthanide metal --- hyaluronic acid --- hyaluronidase --- drug combination --- everolimus --- dual-targeting --- magnetic nanoparticles --- monoclonal antibodies --- nanostructured lipid carrier --- platelet membrane --- biomimicry --- plasmonic photothermal therapy --- gold nanorods --- surgery --- bleeding --- dogs --- cats --- stimuli-responsive --- DOX --- SN38 --- CSCs --- single-walled carbon nanotubes --- chirality separation --- NASH --- drug-gene delivery --- near IR hyperspectral imaging --- plasmonics --- copper --- VEGF --- glioblastoma --- differentiated neuroblastoma --- peptidomimetics --- real-time quantitative polymerase chain reaction (qPCR) --- actin --- combinatorial therapy --- anticancer and antibacterial activity --- temoporfin --- drug-in-cyclodextrin-in-liposome --- hybrid nanoparticles --- multicellular tumor spheroids --- cyclodextrins --- photodynamic therapy article --- yet reasonably common within the subject discipline --- antitumor strategy --- biomimetic core–shell nanoparticles --- NK cell-derived exosomes --- folate receptor --- albumin nanoparticle --- microfluidic --- cabazitaxel --- polydopamine nanoparticles --- size --- cytotoxicity --- iron affinity --- FA-DABA-SMA --- self-assembly --- oncogenic proteins --- intracellular disruption --- folic receptor alpha --- pancreatic cancer --- parvifloron D --- albumin --- erlotinib --- photodynamic therapy --- lipid nanoparticles --- tumor vectorization --- verteporfin --- ovarian carcinomatosis --- spheroids --- integrin --- RGD peptide --- cancer diagnosis --- radiotherapy --- hyperthermia therapy --- biomimetic --- nanocarrier --- membrane-wrapped --- cancer --- targeted delivery --- photothermal therapy --- imaging --- cancer nanomedicine --- tumor microenvironment --- nano–bio interactions --- clinical translation --- magnetic nanowires --- magnetic hyperthermia --- magnetic actuation --- magnetic drug targeting --- titanate nanotubes --- gold nanoparticles --- vectorization --- colloidal stability --- docetaxel --- prostate cancer --- mangiferin --- anti-topoisomerase activity --- extracellular vesicles --- exosomes --- chemico-physical functionalization --- loading --- translational medicine --- nanotechnology: bioengineering --- anacardic acid --- mitoxantrone --- targeted drug delivery --- liposomes --- melanoma --- apoptosis --- ascorbic acid --- angiogenesis --- epithelial-to-mesenchymal transition --- hypoxia --- immunosuppression --- metabolism --- nanotherapeutics --- tumour microenvironment --- DNA origami --- liposome --- remote loading --- acute toxicity --- organoids --- magnetic silica-coated iron oxide nanochains --- photothermal treatment --- hyperthermia --- collagen --- cellular microenvironment --- lymphadenectomy --- magnetometer --- sentinel lymph node dissection --- SPION --- superparamagnetic iron oxide nanoparticles --- Vδ2 T cells --- zoledronic acid --- polymeric nanoconstruct --- anti-tumor immunity --- colorectal carcinoma --- β-cyclodextrin nanosponges --- BALB-neuT mice --- brain tumours --- glioma --- blood brain barrier --- polymeric nanoparticles --- PEGylation --- dioleoylphosphatidylethanolamine --- poly(hydroxyethyl acrylate-co-allyl methyl sulfide) copolymer --- folate --- oxidation-sensitive release --- cellular interaction --- in vitro anti-cancer activity --- triple negative breast cancer --- organotin --- mesoporous silica nanoparticles --- MDA-MB-231 --- theranostic nanomaterials --- nanobiotechnology --- molecular imaging --- nanosystems --- nanomicelles --- ovarian cancer --- tumour targeting --- chemotherapeutics --- riboflavin --- vitamin B2 --- nanomedicines --- secondary structure --- mixed micelle --- pH responsive --- targeted therapy --- anti-cancer --- shear stress --- flow --- in vitro --- therapeutics --- diagnostics --- Immunotherapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This special issue brings together cutting edge research and insightful commentary on the currentl state of the Cancer Nanomedicine field.

Technology: general issues --- antibody drug conjugate (ADC) --- PD-L1 --- tumor spheroid disruption --- immune modulation --- doxorubicin --- graphene oxide --- adsorption --- cathepsin D --- cathepsin L --- anti-metastatic enzyme cancer therapy --- nanoparticles --- targeted delivery system --- siRNA --- osteopontin --- mammary carcinoma --- mesenchymal stem cells (MSCs) --- TAT peptide --- PLGA --- paclitaxel --- nano-engineered MSCs --- orthotopic lung tumor model --- intracranial glioma --- immunotherapy --- CPMV --- viral nanoparticles --- in situ vaccine --- albumin nanoparticles --- microbubble --- ultrasound --- theranostics --- hepatocellular carcinoma --- VX2 tumor --- intra-arterial chemotherapy --- lung cancer --- nanomedicine --- clinical status --- cancer therapy --- breast cancer --- cell signaling --- active targeting --- passive targeting --- EPR effect --- oncogenes --- nanoparticle --- drug delivery --- ligand --- tumor targeting --- biodistribution --- Mesoporous silica nanoparticle --- drug delivery system --- target treatment --- lanthanide metal --- hyaluronic acid --- hyaluronidase --- drug combination --- everolimus --- dual-targeting --- magnetic nanoparticles --- monoclonal antibodies --- nanostructured lipid carrier --- platelet membrane --- biomimicry --- plasmonic photothermal therapy --- gold nanorods --- surgery --- bleeding --- dogs --- cats --- stimuli-responsive --- DOX --- SN38 --- CSCs --- single-walled carbon nanotubes --- chirality separation --- NASH --- drug-gene delivery --- near IR hyperspectral imaging --- plasmonics --- copper --- VEGF --- glioblastoma --- differentiated neuroblastoma --- peptidomimetics --- real-time quantitative polymerase chain reaction (qPCR) --- actin --- combinatorial therapy --- anticancer and antibacterial activity --- temoporfin --- drug-in-cyclodextrin-in-liposome --- hybrid nanoparticles --- multicellular tumor spheroids --- cyclodextrins --- photodynamic therapy article --- yet reasonably common within the subject discipline --- antitumor strategy --- biomimetic core–shell nanoparticles --- NK cell-derived exosomes --- folate receptor --- albumin nanoparticle --- microfluidic --- cabazitaxel --- polydopamine nanoparticles --- size --- cytotoxicity --- iron affinity --- FA-DABA-SMA --- self-assembly --- oncogenic proteins --- intracellular disruption --- folic receptor alpha --- pancreatic cancer --- parvifloron D --- albumin --- erlotinib --- photodynamic therapy --- lipid nanoparticles --- tumor vectorization --- verteporfin --- ovarian carcinomatosis --- spheroids --- integrin --- RGD peptide --- cancer diagnosis --- radiotherapy --- hyperthermia therapy --- biomimetic --- nanocarrier --- membrane-wrapped --- cancer --- targeted delivery --- photothermal therapy --- imaging --- cancer nanomedicine --- tumor microenvironment --- nano–bio interactions --- clinical translation --- magnetic nanowires --- magnetic hyperthermia --- magnetic actuation --- magnetic drug targeting --- titanate nanotubes --- gold nanoparticles --- vectorization --- colloidal stability --- docetaxel --- prostate cancer --- mangiferin --- anti-topoisomerase activity --- extracellular vesicles --- exosomes --- chemico-physical functionalization --- loading --- translational medicine --- nanotechnology: bioengineering --- anacardic acid --- mitoxantrone --- targeted drug delivery --- liposomes --- melanoma --- apoptosis --- ascorbic acid --- angiogenesis --- epithelial-to-mesenchymal transition --- hypoxia --- immunosuppression --- metabolism --- nanotherapeutics --- tumour microenvironment --- DNA origami --- liposome --- remote loading --- acute toxicity --- organoids --- magnetic silica-coated iron oxide nanochains --- photothermal treatment --- hyperthermia --- collagen --- cellular microenvironment --- lymphadenectomy --- magnetometer --- sentinel lymph node dissection --- SPION --- superparamagnetic iron oxide nanoparticles --- Vδ2 T cells --- zoledronic acid --- polymeric nanoconstruct --- anti-tumor immunity --- colorectal carcinoma --- β-cyclodextrin nanosponges --- BALB-neuT mice --- brain tumours --- glioma --- blood brain barrier --- polymeric nanoparticles --- PEGylation --- dioleoylphosphatidylethanolamine --- poly(hydroxyethyl acrylate-co-allyl methyl sulfide) copolymer --- folate --- oxidation-sensitive release --- cellular interaction --- in vitro anti-cancer activity --- triple negative breast cancer --- organotin --- mesoporous silica nanoparticles --- MDA-MB-231 --- theranostic nanomaterials --- nanobiotechnology --- molecular imaging --- nanosystems --- nanomicelles --- ovarian cancer --- tumour targeting --- chemotherapeutics --- riboflavin --- vitamin B2 --- nanomedicines --- secondary structure --- mixed micelle --- pH responsive --- targeted therapy --- anti-cancer --- shear stress --- flow --- in vitro --- therapeutics --- diagnostics --- Immunotherapy